524 related articles for article (PubMed ID: 21623239)
1. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
2. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
3. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
5. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
7. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
8. Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
Fujimoto D; Shimizu R; Kato R; Sato Y; Kogo M; Ito J; Teraoka S; Otoshi T; Nagata K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Anticancer Res; 2015 Nov; 35(11):6261-6. PubMed ID: 26504060
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease.
Tsutani Y; Mimura T; Kai Y; Ito M; Misumi K; Miyata Y; Okada M
J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1089-1096.e1. PubMed ID: 28483268
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
11. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
12. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H; Naito T; Omae K; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Endo M; Harada H; Takahashi T
J Cancer; 2018; 9(11):2054-2060. PubMed ID: 29896291
[No Abstract] [Full Text] [Related]
13. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.
Watanabe T; Minezawa T; Hasegawa M; Goto Y; Okamura T; Sakakibara Y; Niwa Y; Kato A; Hayashi M; Isogai S; Kondo M; Yamamoto N; Hashimoto N; Imaizumi K
BMC Pulm Med; 2019 Nov; 19(1):194. PubMed ID: 31675941
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis.
Kono M; Fujita Y; Takeda K; Miyashita K; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Enomoto N; Nakamura Y; Suda T; Nakamura H
Respir Med; 2019; 154():122-126. PubMed ID: 31238182
[TBL] [Abstract][Full Text] [Related]
16. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
Kato M; Shukuya T; Takahashi F; Mori K; Suina K; Asao T; Kanemaru R; Honma Y; Muraki K; Sugano K; Shibayama R; Koyama R; Shimada N; Takahashi K
BMC Cancer; 2014 Jul; 14():508. PubMed ID: 25012241
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
Glick D; Lyen S; Kandel S; Shapera S; Le LW; Lindsay P; Wong O; Bezjak A; Brade A; Cho BCJ; Hope A; Sun A; Giuliani M
Clin Lung Cancer; 2018 Mar; 19(2):e219-e226. PubMed ID: 29066051
[TBL] [Abstract][Full Text] [Related]
19. Effect of collagen vascular disease-associated interstitial lung disease on the outcomes of lung cancer surgery.
Maeda H; Kanzaki M; Sakamoto K; Isaka T; Oyama K; Murasugi M; Onuki T
Surg Today; 2017 Sep; 47(9):1072-1079. PubMed ID: 28247107
[TBL] [Abstract][Full Text] [Related]
20. Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?
Tang H; Ren Y; She Y; Dai C; Wang T; Su H; Sun W; Jiang G; Chen C
Ther Adv Respir Dis; 2020; 14():1753466620971137. PubMed ID: 33167797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
